- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02545842
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
Titration Target for Chinese Type 2 Diabetes Mellitus Patients Using Insulin Glargine to Achieve Glycaemic Goals: An Assessment of Three Different Fasting Plasma Glucose Targets - BEYOND III/FPG GOAL Study
Primary Objective:
To identify a best fasting plasma glucose (FPG) target for Chinese type 2 diabetes patients using insulin glargine which can provide the highest control rate of glycated hemoglobin (HbA1c) < 7%.
Secondary Objectives:
The control rate of HbA1c ≤6.5% achievement. The control rate of HbA1c <7.0% in patients achieving their FPG target. The percentage of HbA1c <7% without hypoglycemia. The percentage of patients achieving the FPG target without hypoglycemia. The percentage of patients achieving the FPG target and post prandial glucose (PPG) target (2-hour post breakfast <10 mmol/L).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
-
Anshan, China
- Investigational Site Number 156053
-
Beijing, China
- Investigational Site Number 156006
-
Beijing, China
- Investigational Site Number 156001
-
Beijing, China
- Investigational Site Number 156002
-
Changchun, China, 130033
- Investigational Site Number 156013
-
Changchun, China, 130033
- Investigational Site Number 156014
-
Changde, China, 415000
- Investigational Site Number 156022
-
Changsha, China
- Investigational Site Number 156017
-
Changzhou, China
- Investigational Site Number 156034
-
Chenzhou, China
- Investigational Site Number 156023
-
Guangzhou, China, 510515
- Investigational Site Number 156026
-
Haikou, China, 570102
- Investigational Site Number 156029
-
Haikou, China
- Investigational Site Number 156028
-
Haikou, China
- Investigational Site Number 156040
-
Hangzhou, China, 310013
- Investigational Site Number 156039
-
Hangzhou, China
- Investigational Site Number 156038
-
Hangzhou, China
- Investigational Site Number 156042
-
Hangzhou, China
- Investigational Site Number 156044
-
Hefei, China
- Investigational Site Number 156048
-
Hefei, China
- Investigational Site Number 156050
-
Kunming, China
- Investigational Site Number 156011
-
Kunming, China
- Investigational Site Number 156052
-
Lanzhou, China
- Investigational Site Number 156016
-
Lishui, China
- Investigational Site Number 156041
-
Nanchang, China, 330006
- Investigational Site Number 156020
-
Nanchang, China
- Investigational Site Number 156018
-
Nanchang, China
- Investigational Site Number 156019
-
Nanjing, China
- Investigational Site Number 156031
-
Nanjing, China
- Investigational Site Number 156043
-
Nanjing, China
- Investigational Site Number 156049
-
Shanghai, China
- Investigational Site Number 156035
-
Shanghai, China
- Investigational Site Number 156036
-
Shanghai, China
- Investigational Site Number 156047
-
Shantou, China
- Investigational Site Number 156027
-
Shenyang, China
- Investigational Site Number 156015
-
Shijiazhuang, China
- Investigational Site Number 156054
-
Tangshan, China, 063000
- Investigational Site Number 156007
-
Tianjin, China, 300032
- Investigational Site Number 156010
-
Wuhan, China, 430000
- Investigational Site Number 156055
-
Xuzhou, China
- Investigational Site Number 156037
-
Yangzhou, China
- Investigational Site Number 156033
-
Yueyang, China
- Investigational Site Number 156030
-
Zhenjiang, China, 212001
- Investigational Site Number 156032
-
Zhuzhou, China, 412000
- Investigational Site Number 156025
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion criteria :
- 18 to 65 years old.
- Type 2 diabetes patients insufficient controlled by 1-3 oral anti-hyperglycemic drugs (OADs) with stable dose at least 3 months:
If on 1 OAD, provided with the following doses (including but not limited to):
- α-glucosidase inhibitor: 100mg, three times a day (tid);
- metformin: 1.5-2.0 g/day;
- sulphonylureas: sub-maximum (half dose above) to maximum tolerated dose;
- thiazolidinediones: eg. pioglitazone, 30-40 mg/day.
- Besides the medications listed above, if on 1 OAD, others should be maximum tolerated dose allowed in package insert.
- If on 2-3 OADs, any range of dose is acceptable.
- HbA1c >7%, and ≤10.5%.
- FPG >7 mmol/L.
- Body mass index (BMI) ≥20 kg/m^2, and ≤40 kg/m^2.
- Diabetes duration ≥1 year.
- Physician decides to and the patient is willing to start basal insulin (BI) treatment.
- Willing to join the study and sign the informed consent.
Exclusion criteria:
- Type 1 diabetes patients.
- Patients with acute diabetic complications (including unexplained severe hypoglycemia in the last 6 months).
- Previous treatment with insulin for more than 1 month cumulatively in last 1 year, or treatment with insulin in the last 3 months before the screening.
- Known hypoglycemia unawareness or recurrent hypoglycemia.
- Hypersensitivity to study drug or its excipients.
- Any clinically significant acute major organ or systemic disease, or any other situation judged by the Investigator, that is difficult for the 24 weeks follow-up.
- Pregnancy or breastfeeding women.
- Have any mental disorders, lack self-control or not able to express accurately.
- Involved in another clinical trial simultaneously or within a 1 month before start of trial.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Group 1
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=5.6 mmol/L
|
Pharmaceutical form: solution Route of administration: subcutaneous
Andere Namen:
|
Experimental: Group 2
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=6.1 mmol/L
|
Pharmaceutical form: solution Route of administration: subcutaneous
Andere Namen:
|
Experimental: Group 3
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=7.0 mmol/L
|
Pharmaceutical form: solution Route of administration: subcutaneous
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Percentage of patients with HbA1c <7% achievement
Zeitfenster: 24 weeks
|
24 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Percentage of patients achieving HbA1c <=6.5%
Zeitfenster: 24 weeks
|
24 weeks
|
Percentage of patients achieving FPG target with HbA1c <7%
Zeitfenster: 24 weeks
|
24 weeks
|
Percentage of patients achieving HbA1c <7% without hypoglycemia
Zeitfenster: 24 weeks
|
24 weeks
|
Percentage of patients achieving the FPG target without hypoglycemia
Zeitfenster: 24 weeks
|
24 weeks
|
Percentage of patients achieving FPG target
Zeitfenster: 24 weeks
|
24 weeks
|
Percentage of patients achieving PPG target (2-hour post-breakfast <10 mmol/L)
Zeitfenster: 24 weeks
|
24 weeks
|
Change from baseline in HbA1c
Zeitfenster: Baseline to 24 weeks
|
Baseline to 24 weeks
|
Change in FPG
Zeitfenster: 8 weeks to 24 weeks
|
8 weeks to 24 weeks
|
Change in PPG
Zeitfenster: Baseline to 24 weeks
|
Baseline to 24 weeks
|
Change in insulin doses in each arm
Zeitfenster: 1 week to 24 weeks
|
1 week to 24 weeks
|
Change in body weight in each treatment arm
Zeitfenster: Baseline to 24 weeks
|
Baseline to 24 weeks
|
Percentage of patients experienced hypoglycemic events
Zeitfenster: 24 weeks
|
24 weeks
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Wang X, Wu G, Shen D, Zhang X, Yang W. Unmet Needs of Glycaemic Control and Risk Factors of Residual Hyperglycaemia in a Chinese Population with Type 2 Diabetes Initiating Basal Insulin: A Post Hoc Analysis of the FPG GOAL Study. Adv Ther. 2022 Jun;39(6):2820-2830. doi: 10.1007/s12325-022-02128-y. Epub 2022 Apr 16.
- Li L, Yang T, Xue Y, Ruan P, Du J, Li Y, Zhang X, Cui N, Yang W. Influence of Fasting Plasma Glucose Targets on Glycemic Variability in Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of the FPG GOAL Trial (BEYOND III). Adv Ther. 2022 Jan;39(1):421-429. doi: 10.1007/s12325-021-01932-2. Epub 2021 Nov 10.
- Ma J, Lei M, Li Y, Zhang X, Cui N, Yang W. Influence of Fasting Glucose Levels on Achieving Glycemic Target in Individuals with Type 2 Diabetes: a Post Hoc Analysis. Adv Ther. 2020 Sep;37(9):3816-3826. doi: 10.1007/s12325-020-01410-1. Epub 2020 Jul 15.
- Yang W, Yang Z, Zhao J, Lu H, Luo T. Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial. Trials. 2016 Sep 26;17(1):470. doi: 10.1186/s13063-016-1588-6.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- LANTUL07190
- U1111-1172-1058 (Andere Kennung: UTN)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Typ 2 Diabetes mellitus
-
SanofiAbgeschlossenDiabetes mellitus Typ 1 – Diabetes mellitus Typ 2Ungarn, Russische Föderation, Deutschland, Polen, Japan, Vereinigte Staaten, Finnland
-
US Department of Veterans AffairsAmerican Diabetes AssociationAbgeschlossenTyp 2 Diabetes mellitusVereinigte Staaten
-
University Hospital Inselspital, BerneAbgeschlossen
-
Daewoong Pharmaceutical Co. LTD.AbgeschlossenT2DM (Typ-2-Diabetes mellitus)Korea, Republik von
-
Daewoong Pharmaceutical Co. LTD.AbgeschlossenT2DM (Typ-2-Diabetes mellitus)Korea, Republik von
-
Novartis PharmaceuticalsAbgeschlossenTyp-2-Diabetes mellitus (T2DM)Vereinigte Staaten
-
Merck Sharp & Dohme LLCAbgeschlossenTyp-2-Diabetes mellitus (T2DM)
-
AstraZenecaBristol-Myers SquibbAbgeschlossen
-
Novartis PharmaceuticalsAbgeschlossenTyp-2-Diabetes mellitus (T2DM)Japan
-
PegBio Co., Ltd.RekrutierungTyp-2-Diabetes mellitus (T2DM)China, Taiwan, Hongkong
Klinische Studien zur INSULIN GLARGINE
-
SanofiAbgeschlossen
-
IRCCS San RaffaeleBeendetTyp 2 Diabetes mellitus | Periphere GefäßerkrankungItalien
-
Johns Hopkins UniversityBeendetHypoglykämie | Diabetes Typ 1Vereinigte Staaten
-
Novo Nordisk A/SAbgeschlossenDiabetes mellitus, Typ 2Vereinigte Staaten, Polen, Puerto Rico, Kanada, Ungarn, Deutschland, Truthahn, Griechenland
-
Indonesia UniversityUnbekannt
-
SanofiAbgeschlossenDiabetes mellitus Typ 2Deutschland
-
SanofiAbgeschlossenDiabetes mellitus Typ 1Vereinigte Staaten, Kanada, Tschechische Republik, Dänemark, Estland, Finnland, Ungarn, Japan, Lettland, Niederlande, Puerto Rico, Rumänien, Schweden
-
University of AarhusAbgeschlossenDiabetes mellitus, Typ 1Dänemark
-
SanofiAbgeschlossenDiabetes mellitus Typ 1Vereinigte Staaten
-
Vanderbilt University Medical CenterSanofiAbgeschlossen